Insights

Gathering insights about iAnthus…

Similar companies to iAnthus

iAnthus Tech Stack

iAnthus uses 8 technology products and services including Fusion Ads, Gravatar, Twemoji, and more. Explore iAnthus's tech stack below.

Fusion Ads
Advertising
Gravatar
Audio, Video, Graphics
Twemoji
Font Scripts
Google Fonts API
Font Scripts
spin.js
Javascript Frameworks
jQuery
Javascript Libraries
Yoast SEO
Search Engines
MediaElement.js
Video Players

Media & News

Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function
Dec 23, 2025 | www.globenewswire.com
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
NEW YORK and WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida.
Nov 24, 2025 | www.globenewswire.com
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $3,221,132.67 in Stock
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) EVP Simrat Randhawa sold 87,507 shares of Dianthus Therapeutics stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $36.81, for a total value of $3,221,132.67. Following the sale, the executive vice president directly owned 4,000 shares of the company's
Nov 17, 2025 | www.defenseworld.net
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $4,158,442.34 in Stock
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) EVP Simrat Randhawa sold 109,031 shares of the business's stock in a transaction on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the sale, the executive vice president directly owned 4,000 shares in the company,
Nov 17, 2025 | www.defenseworld.net
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 12-Month High – Here’s Why
Shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) hit a new 52-week high on Saturday. The stock traded as high as $41.15 and last traded at $40.85, with a volume of 1574910 shares traded. The stock had previously closed at $35.50. Analyst Ratings Changes A number of brokerages have weighed in on
Nov 17, 2025 | www.defenseworld.net
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.74 per share a year ago.
Nov 05, 2025 | www.zacks.com
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy measures at Week 13 in Phase 2 MaGic trial in gMG New claseprubart data from the MaGic open-label extension supporting potential for 300mg/2mL Q4W dosing and new in vitro data highlighting potential efficacy benefits of upstream (aC1s, claseprubart) vs. downstream (C5, ravulizumab) complement inhibition were presented during the AANEM Annual Meeting in October 2025 Phase 3 gMG trial including two claseprubart treatment arms, 300mg/2mL Q2W and 300mg/2mL Q4W, vs.
Nov 05, 2025 | www.globenewswire.com

iAnthus's Email Address Formats

iAnthus uses at least 2 format(s):

iAnthus Email Formats	Example	Percentage
First.Last@ianthus.com	John.Doe@ianthus.com	100%
First.Last@ianthuscapital.com	John.Doe@ianthuscapital.com	100%

Frequently Asked Questions

Where is iAnthus's headquarters located?

iAnthus's main headquarters is located at 420 Lexington Avenue, Suite 300. The company has employees across 1 continents, including North America.

What is iAnthus's phone number?

You can contact iAnthus's main corporate office by phone at

+1-212-479-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is iAnthus's stock symbol?

iAnthus is a publicly traded company; the company's stock symbol is DNTH.

What is iAnthus's official website and social media links?

iAnthus's official website is ianthuscapital.com and has social profiles on LinkedIn Crunchbase.

What is iAnthus's SIC code NAICS code?

iAnthus's SIC code is 8093 - Specialty Outpatient Facilities, Not Elsewhere Classified NAICS code is 621399 - Offices of All Other Miscellaneous Health Practitioners.

How many employees does iAnthus have currently?

As of December 2025, iAnthus has approximately 501 employees across 1 continents, including North America. Key team members include Vice President Information Technology: T. E.Vice President Operations: P. S.Vice President , Finance: C. K.. Explore iAnthus's employee directory with LeadIQ.

What industry does iAnthus belong to?

iAnthus operates in the Alternative Medicine industry.

What technology does iAnthus use?

iAnthus's tech stack includes Fusion AdsGravatarTwemojiGoogle Fonts APIspin.jsjQueryYoast SEOMediaElement.js.

What is iAnthus's email format?

iAnthus's email format typically follows the pattern of First.Last@ianthus.com. Find more iAnthus email formats with LeadIQ.

When was iAnthus founded?

iAnthus was founded in 2014.

iAnthus

Q: What is iAnthus's official website and social media links?

iAnthus's official website is ianthuscapital.com. iAnthus has social profiles on LinkedIn.

Q: How many employees does iAnthus have currently?

iAnthus has approximately 501 employees.

Q: What technology does iAnthus use?

iAnthus's tech stack includes Twemoji, reCAPTCHA, Underscore.js, Font Awesome, Lightbox.

Alternative MedicineNew York, United States501-1000 Employees

iAnthus delivers a comprehensive solution for financing and managing licensed cannabis cultivators, processors and dispensaries throughout the United States. Founded by entrepreneurs with decades of experience in investment banking, corporate finance, law and healthcare services, iAnthus provides a unique combination of capital and hands-on operating and management expertise. We harness these skills to support a diversified portfolio of cannabis industry investments for our shareholders, including direct equity investments in for-profit license holders and lending facilities coupled with management services to not-for-profit license holders.

Company Overview

Headquarters: 420 Lexington Avenue, Suite 300
Phone number: +1-212-479-****
Website: ianthuscapital.com
SIC Code: 8093 - Specialty Outpatient Facilities, Not Elsewhere Classified
Stock Symbol: DNTH
NAICS Code: 621399 - Offices of All Other Miscellaneous Health Practitioners
Founded: 2014
Employees: 501-1000

Media & News

Funding & Financials

$100M$250M
iAnthus's revenue is estimated to be in the range of $100M$250M

Funding & Financials

$100M$250M
iAnthus's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to iAnthus

TerrAscend

WILL Cannabis Group

Medicine Man Technologies

MedMen

Columbia Care

Cresco Labs

iAnthus Tech Stack

Media & News

Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference

Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $3,221,132.67 in Stock

Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $4,158,442.34 in Stock

Dianthus Therapeutics (NASDAQ:DNTH) Hits New 12-Month High – Here’s Why

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

iAnthus's Email Address Formats

Frequently Asked Questions

Where is iAnthus's headquarters located?

What is iAnthus's phone number?

What is iAnthus's stock symbol?

What is iAnthus's official website and social media links?

What is iAnthus's SIC code NAICS code?

How many employees does iAnthus have currently?

What industry does iAnthus belong to?

What technology does iAnthus use?

What is iAnthus's email format?

When was iAnthus founded?

iAnthus

Company Overview

Media & News

Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference

Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $3,221,132.67 in Stock

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?